Ponesimod
Evidence-based neurology checklist on ponesimod: Mechanism Ponesimod is a selective sphingosine-1-phosphate receptor (S1PR) modulator It sequesters lymphocytes in lymphoid organs Its effect is rapidly reversible on discontinuation Dose Cardiorespiratory side effects Neurological side effects…
Mechanism
- Ponesimod is a selective sphingosine-1-phosphate receptor (S1PR) modulator
- It sequesters lymphocytes in lymphoid organs
- Its effect is rapidly reversible on discontinuation
Dose
Cardiorespiratory side effects
Neurological side effects
Systemic effects
Infectious side effects
Laboratory side effects
Infection screen
Monitoring investigations
Other investigations
Indications to discontinue treatment
References
- D'Ambrosio D, Freedman MS, Prinz J. Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases. Ther Adv Chronic Dis 2016; 7:18-33.
- Olsson T, Boster A, Fernández Ó, et al. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. JNNP 2014; 85:1198-208.
- Kappos L, Fox RJ, Burcklen M, et al. Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial. JAMA Neurol 2021; 78:558-567.
- Wiendl H, Gold R, Berger T, et al. Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Ther Adv Neurol Disord 2021; 14:17562864211039648.
